Go to main content | Go to main menu | Go to search

Project information
Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies

Project Identification
MSM0021622430
Project Period
1/2007 - 12/2013
Investor / Pogramme / Project type
Ministry of Education, Youth and Sports of the CR
  • Research Intents
MU Faculty or unit
Faculty of Medicine
Other MU Faculty/Unit
Faculty of Science
Other MU Faculty/Unit
Faculty of Informatics
Other MU Faculty/Unit
Central European Institute of Technology
Keywords
embryonic stem cells

The goal of this project will be a) to profit from availability of unique cellular resources - mouse and human embryonic stem cells and normal and malignant hematopoietic stem/progenitor cells, b) to effectively employ a wide variety of current and complementary methodologies available to the consortium, and c) to exploit a proven/certified expertise in working with various living systems that span from in vitro cultured cells, through animal models to oncohematological patients. All this together will represent a powerful experimental platform aimed at addressing a nature of molecules and molecular mechanisms underlaying phenomena that are common to both normal and cancer stem cells, mainly their ability to self-renew and to enter differentiation pathways. Integral part of this general goal is to implement multifaceted analytical approach that will cover studies of gene expression at both mRNA and protein levels, evaluating function of extra and intracellular signaling pathways, and analyzing biological properties of cells in vitro and in vivo. Expected outcome will be not only understanding but also a definition of molecules and/or molecular pathways to be tested as therapeutic targets, and cellular models that will make such testing feasible.

Publications

Total number of publications: 361

2012

Previous 1 … 7 8 9 10 11 … 37 Next

You are running an old browser version. We recommend updating your browser to its latest version.